Exchange
TPEx
Every company in the roster listed on TPEx.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
9 of 9 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 TaiMed Biologics4147 · TPEx | 2 assets: 1 approved, 1 Ph 2 | TMB-365 / TMB-380Phase 2 · HIV | May 2027TMB-365 / TMB-380 · Phase 2 |
 AP Biosciences Inc.6945 · TPEx | 1 asset: 1 Ph 2 | AP203Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2026AP203 · Phase 1/2 |
 Alar Pharmaceuticals6785 · TPEx | 1 asset: 1 Ph 1 | ALA-3000Phase 1 · Major Depressive DisorderPartial signal | None on record |
 Anbogen Therapeutics, Inc.7784 · TPEx | 1 asset: 1 Ph 2 | ABT-101Phase 1/2 · Non-Small Cell Lung Cancer | Nov 2026ABT-101 · Phase 1/2 |
 Foresee Pharmaceuticals6576 · TPEx | 1 asset: 1 Ph 2 | MirivadelgatPhase 2 · Hypertension | Feb 2028Mirivadelgat · Phase 2 |
 Genovate Biotechnology4130 · TPEx | 1 asset: 1 Ph 3 | PMR (cilostazol ER)Phase 3 · Atherosclerotic Cardiovascular DiseaseWeak signal | None on record |
 OBI Pharma, Inc4174 · TPEx | 1 asset: 1 Ph 2 | OBI-833Phase 2 · Non-Small Cell Lung Cancer | None on record |
 Oneness Biotech4743 · TPEx | 1 asset: 1 Ph 2 | FB825Phase 2 · Atopic DermatitisWeak signal | 31 May 2027FB825 · Phase 2 |
 PharmaEngine4162 · TPEx | 1 asset: 1 Ph 1 | PEP07Phase 1 · Acute Myeloid Leukemia | 31 Dec 2026PEP07 · Phase 1 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).